YARDLEY, Pa., Nov. 17, 2017 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ENT and allergy
specialists, today announced that Chief Executive Officer Peter Miller will present at the 29th Annual Piper Jaffray Healthcare Conference November 29, 2017, at 11 am ET in New
York. To listen to a webcast of the presentation live, please visit the Investors page of the Optinose website. A replay of the webcast will be available for 90 days
following the conclusion of the event.
About Optinose®
Optinose is a specialty pharmaceutical company on a mission to improve lives with a focus on patients cared for by ear, nose and
throat (ENT) and allergy specialists. The Company’s first two products rely on our patented Exhalation Delivery Systems (EDS),
which are capable of deep intranasal deposition of medication. These exhalation delivery systems enable the creation of products
with potential for meaningful new clinical benefits. Optinose developed its first product,
Onzetra® Xsail® (sumatriptan nasal powder), through the completion of Phase 3 and subsequently
out-licensed the product to Otsuka Pharmaceutical Co., Ltd. Onzetra Xsail received FDA approval and was launched in the U.S. in
2016. The Company’s second product, XHANCE (fluticasone propionate) nasal spray, is approved for the treatment of nasal polyps in
patients 18 years of age and older and is in development for the treatment of chronic sinusitis. Subsequent Optinose pipeline
products will aim to serve the needs of patients treated by ENT and allergy specialists and are expected to include products using
EDS as well as other technologies. The Company is also currently engaged in the early development of products for neurologic orphan
diseases for which the “nose-to-brain” application of an EDS may enable improved treatment. This includes OPN-300 (autism and
others) and OPN-21 (narcolepsy and others). Optinose has corporate offices in the U.S., U.K. and Norway. To learn more,
please visit www.optinose.com.
Optinose Media Contact
Kate Traynor, Sloane & Company
Ktraynor@sloanepr.com
212.446.1871
